2020-11-19
Lipocalin 2 as a potential systemic biomarker for central serous chorioretinopathy
Publication
Publication
Scientific Reports , Volume 10 - Issue 1
No systemic biomarker of Central Serous Chorioretinopathy (CSCR) has been identified. Lipocalin 2 (LCN2 or NGAL), alone or complexed with MMP-9 (NGAL/MMP-9), is increased in several retinal disorders. Serum levels of LCN2 and NGAL/MMP-9 were measured in CSCR patients (n = 147) with chronic (n = 76) or acute/recurrent disease (n = 71) and in age- and sex-matched healthy controls (n = 130). Samples with CRP > 5 mg/L, creatinine > 100 µmol/L, and/or urea > 7.5 mmol/L were excluded. Serum LCN2 was lower in CSCR patients than controls (81.4 ± 48.7 vs 107.3 ± 44.5 ng/ml, p < 0.0001), and lower in acute/recurrent CSCR than controls (p < 0.001) and chronic CSCR (p = 0.006). Serum NGAL/MMP-9 was lower in CSCR patients than controls (47.2 ± 40.7 vs 74.1 ± 42.6, p < 0.0001), and lower in acute/recurrent CSCR than controls (p < 0.001) and chronic CSCR (p = 0.002). A ROC curve showed that for LCN2 serum levels, the 80-ng/ml cutoff value allows to discriminate acute/recurrent CSCR from controls with 80.3% sensitivity and 75.8% specificity, and for NGAL/MMP-9 serum levels, a 38-ng/ml cutoff value allows to discriminate acute/recurrent CSCR from controls with 69.6% sensitivity and 80.3% specificity. In both acute and chronic CSCR, low serum LCN2 and NGAL/MMP-9, provide a biological link between the two CSCR forms, and potential susceptibility to oxidative stress and innate immune dysregulation in CSCR.
| Additional Metadata | |
|---|---|
| doi.org/10.1038/s41598-020-77202-y, hdl.handle.net/1765/131684 | |
| Scientific Reports | |
| Organisation | Department of Ophthalmology |
|
Matet, A. (A.), Jaworski, T. (T.), Bousquet, E. (E.), Canonica, J. (J.), Gobeaux, C. (C.), Daruich, A. (A.), … Behar-Cohen, F. (2020). Lipocalin 2 as a potential systemic biomarker for central serous chorioretinopathy. Scientific Reports, 10(1). doi:10.1038/s41598-020-77202-y |
|
